title: Effect on quality of life with a new insulin injection device in elderly patients with diabetes mellitus type 2.
abstract: OBJECTIVE
  The aim was to investigate the efficacy, safety, and satisfaction of a new insulin injection device in elderly subjects with type 2 diabetes on suboptimal glycemic control with two doses of insulin NPH alone.
  
  
  METHODS
  This study was a prospective no-blind study performed. We selected 25 patients (13 men and 12 women) with type 2 diabetes, only treated with two doses of NPH insulin (injection pen device) for more than 6 months, who did not achieved optimal glycemic control. Additional inclusion criterion was age 55 to 75 years (mean 65.6+/-8.6). All subjects were required to be able to comply with the protocol and carry out home blood glucose monitoring.
  
  
  RESULTS
  HbA1c decreased significantly from 7.8% to 7.6% (P<.05) (2.6% decreased from baseline), and breakfast and lunch preprandial glucose controls decreased significantly. Significant decrease was detected in breakfast and dinner postprandial glucose level. Taken the patients as a whole, insulin dose change significantly (29.8+/-10.9 to 28+/-10.8 Ul/day; P<.05). The number of hypoglycemic events during the 3-month treatment was similar than before treatment with Innolet (2.3+/-3.9 to 1.4+/-2.6 events; ns). The summary results indicated significantly improvement satisfaction questionnaire before 23.9+/-9 points and after 34.5+/-6.5 insulin injection device (P<.05).
  
  
  CONCLUSIONS
  Innolet improved glycemic control and satisfaction in a group of elderly patients with diabetes mellitus type 2 previously treated with pen devices.
authors.affiliation: Instituto de Endocrinologia y Nutrición, Facultad de Medicina y Unidad de Apoyo a la Investigación, Hospital Rio Hortega, Universidad de Valladolid, C/perales 16, Valladolid 47130, Spain. dadluis@yahoo.es
authors.forename: D A
authors.initials: DA
authors.lastname: de Luis
authors.forename: R
authors.initials: R
authors.lastname: Aller
authors.forename: L
authors.initials: L
authors.lastname: Cuellar
authors.forename: M C
authors.initials: MC
authors.lastname: Terroba
authors.forename: H F
authors.initials: HF
authors.lastname: Ovalle
authors.forename: O
authors.initials: O
authors.lastname: Izaola
authors.forename: E
authors.initials: E
authors.lastname: Romero
mesh_terms: D000368:Aged; D000375:Aging; D001786:Blood Glucose / Q000032:analysis; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D005260:Female; D005502:Food; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007267:Injections / Q000295:instrumentation*; D007328:Insulin / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D011446:Prospective Studies; D011788:Quality of Life
chemical_list: D001786:Blood Glucose; D006442:Glycated Hemoglobin; D007328:Insulin